The Business Research Company’s report on the Prostate Cancer Diagnostics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the prostate cancer diagnostics market?
The increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics market going forward. Prostate cancer is a condition in which cancer arises in the prostate gland, a component of the male and female reproductive systems. Prostate cancer diagnostics helps patients to diagnose the disease early with various tests, including prostate-specific antigen (PSA) testing and sophisticated imaging techniques. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based non-profit organization dedicated to eliminating cancer, approximately 288,300 new cases of prostate cancer and 34,700 deaths attributed to prostate cancer in 2023. Therefore, the increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics market.
Access Your Free Sample of the Global Prostate Cancer Diagnostics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12003&type=smp
How has the prostate cancer diagnostics market size evolved, and what are the latest forecasts for its expansion?
The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $4.43 billion in 2024 to $5.03 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to the increasing aging population, advancements in medical imaging, rising awareness and screening programs, public health initiatives, and improved biopsy techniques
The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $8.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to the integration of artificial intelligence (AI), growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, and multiparametric MRI for diagnosis. Major trends in the forecast period include liquid biopsy technologies, technological advances in biomarker detection, clinical research and development, digital pathology integration, emergence of multiplex biomarker assays.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12003&type=smp
Which major companies dominate the prostate cancer diagnostics market?
Major companies operating in the prostate cancer diagnostics market include F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc, Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc, NeoGenomics Laboratories Inc., Guardant Health Inc, GRAIL Inc, Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd, Exosome Diagnostics Inc., Dana-Farber Cancer Institute, Cellanyx Diagnostics Inc., A3P Biomedical AB
What trends will shape the future of the professional beauty services market?
Technological innovations are a key trend gaining popularity in the prostate cancer diagnostics market. Major companies operating in prostate cancer diagnostics are introducing innovative AI-powered prostate cancer diagnosis tools to sustain their position in the market. For instance, in March 2023, Qritive, a Singapore-based company that develops diagnostic tools, launched QAi Prostate, an advanced AI-powered prostate cancer diagnosis tool for pathologists. These tools include advanced machine learning algorithms that identify the prostatic adenocarcinoma region and analyze whole slide images of prostate core needle biopsies. This tool helps pathologists to perform accurate diagnoses quickly and reduces the time taken for the treatment.
Which region dominates the prostate cancer diagnostics market, and what factors contribute to its leadership?
North America was the largest region in the prostate cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report
How is the prostate cancer diagnostics market segmented, and which segment holds the largest share?
The prostate cancer diagnostics market covered in this report is segmented –
1) By Products: Instruments, Reagents And Consumables, Accessories
2) By Test Type: Preliminary Tests, Confirmatory Tests
3) By Prostate Cancer: Squamous Cell Cancer, Small Cell Carcinoma, Transitional Cell Cancer, Prostatic Adenocarcinoma, Ductal Adenocarcinoma, Small Cell Prostate Cancer, Acinar Adenocarcinoma
4) By Peer Groups: Adult, Pediatric, Geriatrics
5) By End User: Hospitals, Independent Diagnostic Laboratories, Cancer Research Institutes, Other End-Users
Subsegments:
1) By Instruments: Biopsy Instruments, Imaging Devices, Digital Rectal Examination Tools
2) By Reagents And Consumables: Diagnostic Assay Kits, Staining Reagents, Sample Collection Materials
3) By Accessories: Biopsy Guides, Specimen Handling Accessories, Calibration And Maintenance Tools
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12003
How is the prostate cancer diagnostics market defined?
Prostate cancer diagnostics refers to the process of determining and verifying the presence of prostate cancer using diagnostic testing and medical evaluations to evaluate the status and severity of the illness and direct treatment choices. It is commonly used to treat prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
